Absci utilizes a generative AI-driven Integrated Drug Creation platform that combines AI modeling with scalable wet lab validation to design and optimize biologics for therapeutic applications. This approach significantly reduces the time from drug conception to clinical candidates, enabling the screening of billions of cells weekly and accelerating the development of effective treatments for patients.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Traditional biologics drug discovery is a lengthy, expensive process with a high failure rate, often struggling to identify novel targets and optimize drug candidates effectively. The process from drug conception to clinical candidates can be slow, hindering the rapid development of effective treatments.
Solution
Absci utilizes a generative AI-driven Integrated Drug Creation Platform that combines AI modeling with scalable wet lab validation to design and optimize biologics for therapeutic applications. The platform leverages iterative cycles of wet lab experimentation and AI model building to unlock differentiated biology and design improved biologics. This approach enables the screening of billions of cells weekly, significantly reducing the time from drug conception to clinical candidates. Absci's AI Target Discovery uses reverse immunology to identify antibodies produced by super immune responders, providing an antibody/target pair ready for AI optimization and IND-enabling studies.
Target Audience
Absci partners with leaders across the pharmaceutical, technology, and academic sectors to develop differentiated biologics against challenging targets.
Features
- Generative AI-driven design of biologics from scratch
- Integrated Drug Creation Platform combining AI modeling with wet lab validation
- AI Target Discovery using reverse immunology to identify novel targets
- Multi-parametric lead optimization
- High-throughput screening of billions of cells weekly
- Data generation and model training with 6-week cycle times
- AI-enabled novel target discovery using Reverse Immunology